ALS Biopharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ALS Biopharma - overview
Established
2016
Location
Zurich, -, Switzerland
Primary Industry
Biotechnology
About
Based in Zurich, Switzerland, and founded in 2016 and led by Chief Executive Officer Michael Salzmann, ALS Biopharma operates as a healthcare company providing drug discovery solutions treating neurodegenerative disease. In January 2011, Alzheimer's Drug Discovery Foundation invested USD 0. 22 million in ALS Biopharma, LLC. ALS Biopharma LLC developed therapies and monoclonal antibody drug for treating amyotrophic lateral sclerosis.
The company offers antibody for ALS, a neurodegenerative disease that attacks nerve cells in the brain and spinal cord, enabling patients suffering from this disease to regain their ability to breathe and avoid progressive paralysis of the muscles that control voluntary movement.
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.